Clinical usefulness in geriatric patients of combining CHADS2 and HEMORR2HAGES scores to guide antithrombotic prophylaxis in atrial fibrillation

Aging Clinical and Experimental Research

Volumn 22, Issue 4, 2010, Pages 289-294

  Somme, Dominique ^a   Corvol, Aline ^a,b   Lazarovici, Céline ^a,b   Lahjibi Paulet, Hayat ^a   Gisselbrecht, Mathilde ^a   Saint Jean, Olivier ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Antithrombotic therapy; Atrial fibrillation; Clinical practice study; Scoring system

Indexed keywords

ALCOHOL; ANTICOAGULANT AGENT;

AGED; ALCOHOL ABUSE; ALCOHOLISM; ANEMIA; ARTICLE; CALCULATION; CLINICAL ASSESSMENT TOOL; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; DIABETES MELLITUS; FALL RISK; FEMALE; GERIATRIC ASSESSMENT; HABIT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEREDITY; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; PRESCRIPTION; PROPHYLAXIS; RETROSPECTIVE STUDY; SCORING SYSTEM; STROKE; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS;

EID: 78751689190     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.3275/6709     Document Type: Article

References (20)

1. Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing 2009; 38: 156-62.
2. (No Authors listed) Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. The Clinical Quality Improvement Network (CQIN) Investigators. Can J Cardiol 1998; 14: 695-702.
3. Cohen N, Almoznino-Sarafian D, Alon I et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 2000; 31: 1217-22.
4. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.
5. McCormick D, Gurwitz JH, Goldberg RJ et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001; 161: 2458-63.
6. Nieuwlaat R, Capucci A, Lip GY et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27: 3018-26.
7. Meiltz A, Zimmermann M, Urban P, Bloch A. Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace 2008; 10: 674-80.
8. Monte S, Macchia A, Pellegrini F et al. Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur Heart J 2006; 27: 2217-23.
9. Mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
10. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-96.
11. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48: 854-906.
12. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155: 277-81.
13. Choudhry NK, Anderson GM, Laupacis A, Ross-Degnan D, Normand SL, Soumerai SB. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006; 332: 141-5.
14. Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-9.
15. Howard PA, Ellerbeck EF, Engelman KK, Dunn MI. Warfarin for stroke prevention in octogenarians with atrial fibrillation. Am J Geriatr Cardiol 2001; 10: 139-44.
16. Hansen ML, Gadsboll N, Rasmussen S et al. Clinical consequences of hospital variation in use of oral anticoagulant therapy after first-time admission for atrial fibrillation. J Intern Med 2009; 265: 335-44.
17. Poli D, Antonucci E, Marcucci R et al. Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. Thromb Res 2007; 121: 347-52.
18. Healey JS, Hart RG, Pogue J et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke 2008; 39: 1482-6.
19. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008; 51: 810-5.
20. Wess ML, Schauer DP, Johnston JA et al. Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. J Gen Intern Med 2008; 23: 411-7.